Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.46 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25628434 | 0.88 | AVPR1A (0.47) | SIGMAR1AVPR1AHTR2A | |
| SCHEMBL15428161 | 0.84 | AVPR1A (0.45) | AVPR1ASLC6A2SLC6A4 | |
| SCHEMBL15428164 | 0.82 | AVPR1A (0.44) | AVPR1ASLC6A2SLC6A4 | |
| SCHEMBL25358499 | 0.81 | OPRM1 (0.36) | SIGMAR1AVPR1AOPRM1 | |
| SCHEMBL30623481 | 0.80 | HTR2C (0.42) | DRD2HTR2AHTR2CSLC6A2SLC6A4 | |
| SCHEMBL25356678 | 0.80 | HTR2C (0.42) | DRD2HTR2AHTR2CSLC6A2SLC6A4 | |
| SCHEMBL16835918 | 0.79 | AVPR1A (0.48) | SIGMAR1AVPR1AOPRM1TSHRUSP2 | |
| SCHEMBL16835992 | 0.79 | AVPR1A (0.48) | SIGMAR1AVPR1AOPRM1TSHRUSP2 | |
| SCHEMBL6264633 | 0.78 | AVPR1A (0.47) | AVPR1ATSHR | |
| SCHEMBL4979408 | 0.78 | AVPR1A (0.53) | SIGMAR1AVPR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430022-A1 | 1,2,3-TRIAZOLO Ý4,3-A¨PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | Janssen Pharmaceuticals, Inc. (US) | 2012-03-21 | — | — | EP | claimed |
| WO-2010130424-A9 | 1,2,4-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2011-01-27 | — | — | WO | claimed |
| US-20230106150-A1 | SPIRO-OXAZOLONES | HOFFMANN-LA ROCHE INC. (US) | 2023-04-06 | — | — | US | disclosed |
| US-11578077-B2 | Spiro-oxazolones | HOFFMANN-LA ROCHE INC. (US) | 2023-02-14 | — | — | US | disclosed |
| US-10479796-B2 | Spiro-oxazolones | HOFFMAN-LA ROCHE INC. (US) | 2019-11-19 | — | — | US | disclosed |
| EP-3107916-B1 | SPIRO-OXAZOLONES | HOFFMANN LA ROCHE (CH) | 2019-03-20 | — | — | EP | disclosed |
| US-10071095-B2 | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of neurological and psychiatric disorders | Janssen Pharmaceuticals, Inc. (US) | 2018-09-11 | — | — | US | disclosed |
| EP-3083633-B1 | SPIRO-OXAZOLONES | HOFFMANN LA ROCHE (CH) | 2017-11-29 | — | — | EP | disclosed |
| US-9828385-B2 | Spiro-oxazolones | HOFFMANN-LA ROCHE INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20170333426-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives And Their Use For The Treatment Of Prevention Of Neurological And Psychiatric Disorders | JANSSEN PHARMACEUTICALS INC (US) | 2017-11-23 | — | — | US | disclosed |
| US-20170333426-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives And Their Use For The Treatment Of Prevention Of Neurological And Psychiatric Disorders | JANSSEN PHARMACEUTICALS INC (US) | 2017-11-23 | — | — | US | disclosed |
| US-7279486-B2 | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists | PFIZER INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-20070197500-A1 | 3-(2,3-Dihydro-1'H-spiro[indene-1,4'-piperidin]-1'-yl)-N,N-dimethyl-2-(pyridin-2-ylmethyl)propanamide; opioid receptor-like 1 antagonist; reduced inhibitory activity at HERG potassium channel; analgesic; side effect reduction; neurpathic and other pain | PFIZER, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070191419-A1 | Cycloalkanopyridine derivative | MSD K.K. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1795527-A1 | CARBAMOYL-SUBSTITUTED SPIRO DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-06-13 | — | — | EP | disclosed |
| EP-1732928-A2 | ALPHA ARYL OR HETEROARYL METHYL BETA PIPERIDINO PROPANOIC ACID COMPOUNDS AS ORL1-RECEPTOR ANTAGONISTS | Pfizer, Inc. (US) | 2006-12-20 | — | — | EP | disclosed |
| EP-1726590-A1 | CYCLOALKANOPYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
| US-20050277659-A1 | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists | PFIZER JAPAN INC. (JP) | 2005-12-15 | — | — | US | disclosed |
| WO-2005092895-A2 | ALPHA ARYL OR HETEROARYL METHYL BETA PIPERIDINO PROPANOIC ACID COMPOUNDS AS ORL1-RECEPTOR ANTAGONISTS | PFIZER JAPAN INC. (JP) | 2005-10-06 | — | — | WO | disclosed |
| US-20050153998-A1 | Tetrahydroisoquinoline or isochroman compounds | ITO FUMITAKA (JP) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153998-A1 | Tetrahydroisoquinoline or isochroman compounds | OPRL1, NR1H3, HRH3 | SIGMAR1 11/4885AVPR1A 295/4885OPRM1 8/4885 |
| US-10071095-B2 | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of neurological and psychiatric disorders | GRM2, GRM1, GRIA2 | SIGMAR1 334/4885AVPR1A 463/4885OPRM1 277/4885 |
| US-20050277659-A1 | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists | OPRL1, OGFRL1, ORMDL3 | SIGMAR1 10/4885AVPR1A 609/4885OPRM1 7/4885 |
| US-11578077-B2 | Spiro-oxazolones | AVPR1A, AVPR1B, AVPR2 | SIGMAR1 178/4885AVPR1A 1/4885OPRM1 33/4885 |
| US-20170333426-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives And Their Use For The Treatment Of Prevention Of Neurological And Psychiatric Disorders | GRM2, GRM1, GRIN2C | SIGMAR1 335/4885AVPR1A 491/4885OPRM1 251/4885 |
| US-20070191419-A1 | Cycloalkanopyridine derivative | OPRL1, OPRK1, AVPR2 | SIGMAR1 75/4885AVPR1A 7/4885OPRM1 13/4885 |
| US-20070197500-A1 | 3-(2,3-Dihydro-1'H-spiro[indene-1,4'-piperidin]-1'-yl)-N,N-dimethyl-2-(pyridin-2-ylmethyl)propanamide; opioid receptor-like 1 antagonist; reduced inhibitory activity at HERG potassium channel; analgesic; side effect reduction; neurpathic and other pain | OPRL1, OPRD1, OPRK1 | SIGMAR1 26/4885AVPR1A 476/4885OPRM1 5/4885 |
| US-20230106150-A1 | SPIRO-OXAZOLONES | AVPR1A, AVPR1B, AVPR2 | SIGMAR1 178/4885AVPR1A 1/4885OPRM1 33/4885 |
| US-10479796-B2 | Spiro-oxazolones | AVPR1A, AVPR1B, AVPR2 | SIGMAR1 178/4885AVPR1A 1/4885OPRM1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.